Liposomal doxorubicin is a chemotherapy drug, which is administered intravenously to treat AIDS-related Kaposi's sarcoma, breast cancer, ovarian cancer, and other solid tumors. Doxorubicin acts by blocking an enzyme called topoisomerase 2 that cancer cells need in order to divide and grow. Liposomal delivery of doxorubicin HCL (Hydrochloride) improves drug penetration into tumors and decreases drug clearance, thereby increasing the duration of therapeutic drug effects. Some side effects of using Doxil or doxorubicin hydrochloride liposome include low blood counts, hand-to-foot syndrome (palmar-plantar erythrodysesthesia), mouth sores, infusion-related side effects: shortness of breath, facial swelling, headache, back pain, flushing, tightness in the chest and throat, and/or low blood pressure.

Market Dynamics

The increasing prevalence of cancer is expected to drive demand for liposomal doxorubicin for treatment of the disease and aid in growth of the U.S. liposomal doxorubicin market. For instance, according to the American Cancer Society, in 2017, cancer was the second most common cause of death in the U.S., and accounted for nearly one out of four deaths. Moreover, according to National Cancer Institute, in 2019, around 1.8 million people were diagnosed with cancer in the U.S., and around 276,480 women and 2,670 men were diagnosed with breast cancer.

Key features of the study

• This report provides in-depth analysis of the U.S. liposomal doxorubicin market, and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2026-2033), considering 2025 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the U.S. liposomal doxorubicin market based on the following parameters – company highlights, types portfolio, key highlights, financial performance, and market strategies
• Key companies covered as a part of this study include Johnson & Johnson, Baxter International Inc., Sun Pharmaceutical Industries Ltd., and Dr. Reddy’s Laboratories, Inc.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The U.S. liposomal doxorubicin market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the U.S. liposomal doxorubicin market

Market Segmentation

• By Drug Type (Revenue, USD Mn, 2021-2033)
  • Branded
  • Generic
• By Cancer Type (Revenue, USD Mn, 2021-2033)
  • Ovarian Cancer
  • AIDS-related Kaposi’s Sarcoma
  • Multiple Myeloma
  • Others
• By Region (Revenue, USD Mn, 2021-2033)
  • California
  • Texas
  • Florida
  • New York
  • Pennsylvania
  • Illinois
  • Ohio
  • Georgia
  • North Carolina
  • Michigan
  • New Jersey
  • Virginia
  • Washington
  • Arizona
  • Others
• Key Players
  • Johnson & Johnson
  • Baxter International Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Reddy’s Laboratories, Inc.